NCT01639248

Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC

A Phase II Study of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced and Metastatic Triple-Negative Breast Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 41 (actual)
• Sponsor: CASI Pharmaceuticals, Inc. · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the activity of ENMD-2076 as defined by the clinical benefit rate when patients with previously treated locally advanced or metastatic triple negative breast cancer are treated with daily oral ENMD-2076.

Conditions

• Triple Negative Breast Cancer

Interventions

Type	Name	Description
DRUG	ENMD-2076	250 mg per day in oral capsules in 28 day continuous cycles

Timeline

• Start date: 2012-07-01
• Primary completion: 2017-06-01
• Completion: 2017-06-01
• First posted: 2012-07-12
• Last updated: 2017-06-26

Locations

3 sites across 2 countries: United States, China